Cabaletta Bio Alternatives & Competitors
12 companies similar to Cabaletta Bio — Engineered T cell therapies designed for the treatment of patients with autoimmu...
Companies similar to Cabaletta Bio
Barinthus Biotherapeutics
Barinthus is a clinical-stage biopharmaceutical company developing novel T-cell immunother...
Immunocore
Science to Transform Lives
Imcyse SA
Pioneering the development of Imotopes™ to prevent, stop and potentially cure autoimmune d...
Biodexa Pharmaceuticals PLC
Advancing Medicines for a Brighter Future
Rival Readout
Competing with Cabaletta Bio? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Autolus Therapeutics
Focused on the development of precisely targeted, controlled & highly active T cell therap...
Upstream Bio
Developing treatments for inflammatory diseases
Entelexo Biotherapeutics
Entelexo has created a novel platform technology for engineering exosomes as a new approac...
Aspen Neuroscience, Inc.
Developing autologous iPSC-derived cell replacement therapies for Parkinson’s disease and...
Glyscend Therapeutics
Advancing a new class of oral gut-targeted polymeric drugs for the treatment of T2D and Ob...
Avidity Biosciences, Inc.
At Avidity, we are developing a new class of oligonucleotide-based therapies.
Heartseed Inc.
Clinical-stage biotech company developing iPSC-derived highly purified ventricular cardiom...
Dyne Therapeutics
Advancing life-transforming therapies for serious muscle diseases
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is at the forefront of innovation within the biotechnology sector, focusing on engineered T cell therapies aimed at treating autoimmune diseases. Founded in 2017 and headquartered in Philadelphia, PA, this clinical-stage company is pioneering potentially curative medical treatments, attract...
Development of T cell therapies for autoimmune diseases, Conducting Phase 1/2 clinical trials, CD19 chimeric antigen receptor T cell therapy development, Research and development of CABA® platform
Patients with autoimmune diseases, Healthcare providers specializing in rheumatology, dermatology, and neurology, Biotechnology researchers and collaborators, Investors in biopharmaceuticals
Engineered T Cell Therapies, Autoimmune Diseases, Clinical-stage, CARTA Strategy, CAART Strategy, B Cell-mediated Autoimmune Diseases, CD19-CAR T, Mucosal Pemphigus Vulgaris, MuSK Myasthenia Gravis, Chimeric Antigen Receptor, Autologous CAAR T Cells, Therapeutic Platform, Selective Targeting, Partnership With Penn
B2B, B2D
Product Sales, Licensing, Service Fee
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Cabaletta Bio: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Cabaletta Bio on 9 Jun 2026. The 12 companies listed here were last checked between 23 Feb 2026 and 22 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.